Proteomic analysis of chemotherapy resistance related proteins in human breast cancer cells

• Project/Area Number: 25870924
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Laboratory medicine; Applied pharmacology
• Research Institution: Osaka Medical College
• Principal Investigator: Tanaka Satoru 大阪医科大学, 医学部, 非常勤講師 (50595741)
• Research Collaborator: Sakai Akiko 大阪医科大学, 医学部, 講師
• Project Period (FY): 2013-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: プロテオーム / 乳癌 / タキサン / 化学療法

Outline of Final Research Achievements

To identify the proteins involved in paclitaxel resistance, we compared the proteomes of MCF-7 human breast cancer cells and its paclitaxel-resistant subclone MCF-7/PTX. Using two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time of flight mass spectrometry, many proteins were modulated between these cells. Among them, PROTEIN A were upregulated in MCF-7/PTX cells. Knockdown of PROTEIN A using small interfering RNA in MCF-7/PTX cells restored their sensitivity to paclitaxel.